LENZ Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$7.78(as of May 29, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

LENZ Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$7.78
Ticker SymbolLENZ
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees152
CountyUSA
Market Cap$250.5M
EBIDTA-118.0M
10-Day Moving Average7.44
P/E Ratio-2.24
20-Day Moving Average8.22
Forward P/E Ratio0.00
50-Day Moving Average9.02
Earnings per Share-3.64
200-Day Moving Average22.30
Profit Margin-2,182.43%
RSI42.73
Shares Outstanding31.4M
ATR0.67
52-Week High50.40
Volume837,271
52-Week Low6.61
Most Recent Support Level7.48
Book Value246.5M
Most Recent Resistance Level8.12
P/B Ratio0.99
Upper Keltner9.72
P/S Ratio11.62
Lower Keltner6.71
Debt-to-Equity Ratio9.72
Next Earnings Date07/28/2026
Cash Surplus-1.0M
Next Ex-Dividend DateUnknown

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

LENZ Therapeutics Inc In Our Stock Scanner

As of May 29, 2026
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Mean ReversionScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.